Novo Nordisk is rated a long-term Buy, as falling capital spending supports higher free cash flow, with a DKK 393.21 intrinsic value.
Four-year renewed commitment will help advance the development of much-needed products to prevent, diagnose, and treat dangerous bacterial infectionsHELLERUP, Denmark and BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- The Novo Nordisk Foundation and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced the renewal of their partnership to accelerate the development of an integrated portfolio of innovative products to address bacterial infections and antimicrobi
Analyst maintains a Strong Buy rating on Novo Nordisk at 10.89x non-GAAP earnings as free cash flow guidance rises to DKK 60–70 billion.
Johnson & Johnson's revenue has climbed quarter after quarter, while Novo Nordisk's has stayed largely flat apart from one notable jump.
With millions of patients taking GLP-1 drugs, doctors are discovering rare but worrying problems affecting the body and the mind.
The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.
Novo Nordisk (CPSE:NOVO B) reported positive phase 3 results for its investigational obesity therapy CagriSema, supporting a future filing plan. The company received European Union approval for haemophilia A treatment FREHEMGO, with a launch planned in initial EU markets in 2026. Regulatory submissions for sickle cell disease therapy etavopivat were filed with both the US Food and Drug Administration and the European Medicines Agency. These CagriSema, FREHEMGO and etavopivat updates come...
Novo Nordisk's exploratory CagriSema analyses found 25.4% weight loss among early responders by week 68; a U.S.
Novo Nordisk (CPSE:NOVO B) has partnered with DJ Khaled to promote his Wegovy weight loss journey to a wider US audience. Eli Lilly has received the first Chinese regulatory approval for an oral GLP-1 weight loss pill, ahead of Novo Nordisk's own oral product. Novo Nordisk's obesity portfolio now faces a fresh test as Wegovy promotion coincides with Eli Lilly's oral GLP-1 approval in China. Check out 3 other big wins that Novo Nordisk investors should know about. For a broader view on how...
Novo Nordisk's future hinges on broadening its drug franchises, notably CagriSema and Zenagamtide. Read why NVO stock is a hold.
Novo Nordisk's Q3 2026 beat and overlooked guidance upgrades make medium-term de-rating exceedingly unlikely. Click for more on the NVO stock.
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment
The agency is requiring GLP-1 manufacturers to warn the drugs can increase risk of “eye stroke.”
PERTH, Australia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company ) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is please...
GLP-1 drugs may increase the risk of NAION, a rare optic nerve condition that can lead to sudden vision loss and has no known treatment.
This is the newest page. Registered accounts read further back.